Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, WOM, TRI

Lumenis to Highlight the Positive Impact of its FiberLasetm CO2 Laser Treatment for Ovarian Endometrioma on Ovarian Reserve


YOKNEAM, Israel, October 18, 2017 /PRNewswire/ --

Presenters will feature results of recent successful studies using the innovative technology and its unique operative technique. 

Lumenis Ltd., the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today that it will share new clinical data on its CO2 laser-based FiberLasetm for minimally-invasive treatment of endometriosis at the European Society for Gynecological Endoscopy (ESGE) 26th Annual Congress, October 18- 21 at the Sueno Hotel Belek & Convention Center in Antalya, Turkey.

     (Logo: http://mma.prnewswire.com/media/541530/Lumenis_Logo.jpg )

Endometriosis is a disease that affects roughly 10% of the world's female population. While the etiology of the disease is still unclear, treatment options exist and vary between symptomatic ease, hormonal supplements and hysterectomy when fertility is no longer of concern. Approximately 85% of endometriosis patients are diagnosed with ovarian endometriosis; these cases require delicate and precise treatment options to preserve fertility.

Lumenis has collaborated with leading surgeons worldwide to develop an advanced surgical CO2 FiberLasetm laser procedure, which has been demonstrated to remove endometriosis lesions very delicately and precisely without harming the ovarian reserve. Recent studies[1]-[6] show the treatment results in fast recovery time, less inflammation and pain, low risk of infection and low rate of side effects such as surgery-related adhesions. Patients experience immediate improvement in their quality of life, higher rates of fertility preservation and lower disease recurrence rates compared to RF technology.

At the ESGE Annual Congress, Lumenis will highlight its innovations in treating endometriosis, including the advanced surgical CO2 lasers, UltraPulse® DUO and AcuPulsetm DUO. These laser systems utilize both Free Beam laser delivery and the flexible FiberLasetm fiber, designed to operate precisely around delicate pelvic anatomy with minimal thermal damage while keeping healthy tissue intact, significantly improving symptoms and quality of life while helping to preserve and protect fertility.

Lumenis will host an industry symposium and share the results of the recent study on the efficacy of the AcuPulsetm DUO for removal of endometrial tissue around the ovaries while preserving ovarian antral follicle count and anti-Mu?llerian hormone, both necessary for fertility. Authors Prof. Massimo Candiani and Dr. Jessica Ottolina, and their colleagues will present results of the study titled, "Positive Effects on Ovarian Reserve When Using CO2 Laser Vaporization Versus Cystectomy for the Treatment of Ovarian Endometrioma: A Prospective Randomized Clinical Trial."

The study's author, Prof. Massimo Candiani, Director of Obstetrics and Gynecology at the San Raffaele Hospital in Milan, said, "I consider the CO2 laser a valuable tool in the treatment of pelvic and ovarian endometriosis, where I can easily use it for excision and vaporization. When using the CO2 laser, I can achieve precision and safety and, most importantly, preservation of the ovarian functionality."

"At Lumenis, we take great pride in our company's commitment and continuous innovation in women's health technology," said Lumenis CEO Tzipi Ozer-Armon. "We are very excited to share the clinical and technological advances with our partners and colleagues at the ESGE Annual Congress."

During the ESGE Annual Congress, attendees can visit Lumenis at booth #20 to gain hands-on experience with the Lumenis CO2 laser solutions and attend the company's range of engaging symposia and presentations:


Lumenis will also introduce attendees to http://www.gynhealth.com, a website created by the company to educate endometriosis patients and their families on the disease and its surgical treatment options.

About Lumenis 

http://www.lumenis.com
Lumenis is the world's largest energy-based medical device company for surgical, aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. Regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.

 

References:

  1. Adelman MR, Tsai LJ, Tangchitnob EP, Kahn BS, 2013.J Obstet Gynaecol,33(3): 225-31
  2. Wang Z, Chocat N, 2010. Curr Pharm Biotechno, 11(4):384-97.
  3. Bailey AP, Lancerotto L, Gridley C, Orgill DP, Nguyen H, Pescarini E, Lago G, Gargiulo AR, 2014. J Minim Invasive Gynecol, 21(6):1103-9
  4. Schipper E, Nezhat C, 2012. Int J Womens Health ;4:383- 93
  5. Tsolakidis D, Pados G, Vavilis D, Athanatos D, Tsalikis T, Giannakou A, Tarlatzis BC, 2010. Fertil Steril, 94(1):71-7
  6. Meuleman C, D'Hoore A, Van Cleynenbreugel B, Beks N, D'Hooghe T, 2009. Reprod Biomed Online ;18(2):282-9

MEDIA CONTACT
Kara Stephens, Pascale Communications
[email protected]
407.765.1185


These press releases may also interest you

at 10:45
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
Closed System Transfer Devices Market in terms of revenue was estimated to be worth $1.1 billion in 2024 and is poised to reach $2.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. The...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...



News published on and distributed by: